Last reviewed · How we verify

Sevoflurane + Fentanyl

Azienda Ospedaliera San Gerardo di Monza · Phase 3 active Small molecule

Sevoflurane is a volatile anesthetic that depresses central nervous system activity, while fentanyl is an opioid analgesic that binds to mu-opioid receptors to provide analgesia and sedation.

Sevoflurane is a volatile anesthetic that depresses central nervous system activity, while fentanyl is an opioid analgesic that binds to mu-opioid receptors to provide analgesia and sedation. Used for General anesthesia for surgical procedures, Balanced anesthesia with analgesia during surgery.

At a glance

Generic nameSevoflurane + Fentanyl
SponsorAzienda Ospedaliera San Gerardo di Monza
Drug classGeneral anesthetic + opioid analgesic combination
TargetGABA receptors (sevoflurane); mu-opioid receptors (fentanyl)
ModalitySmall molecule
Therapeutic areaAnesthesiology
PhasePhase 3

Mechanism of action

Sevoflurane acts as a general anesthetic by enhancing inhibitory GABAergic neurotransmission and inhibiting excitatory glutamatergic signaling in the central nervous system, producing unconsciousness and amnesia. Fentanyl potentiates this effect by activating mu-opioid receptors, providing analgesia and additional sedation. Together, this combination is used for balanced anesthesia during surgical procedures.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: